Intech Investment Management LLC Sells 6,815 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Intech Investment Management LLC reduced its stake in United Therapeutics Co. (NASDAQ:UTHR) by 45.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,288 shares of the biotechnology company’s stock after selling 6,815 shares during the period. Intech Investment Management LLC’s holdings in United Therapeutics were worth $2,970,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the stock. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its stake in United Therapeutics by 64.4% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 32,092 shares of the biotechnology company’s stock worth $11,500,000 after purchasing an additional 12,566 shares in the last quarter. Premier Fund Managers Ltd bought a new position in shares of United Therapeutics during the 3rd quarter worth $5,307,000. PNC Financial Services Group Inc. grew its position in shares of United Therapeutics by 14.9% during the 3rd quarter. PNC Financial Services Group Inc. now owns 3,179 shares of the biotechnology company’s stock worth $1,139,000 after buying an additional 412 shares in the last quarter. B. Metzler seel. Sohn & Co. Holding AG purchased a new position in shares of United Therapeutics during the third quarter valued at $344,000. Finally, Pathstone Holdings LLC raised its holdings in shares of United Therapeutics by 4.1% in the third quarter. Pathstone Holdings LLC now owns 4,118 shares of the biotechnology company’s stock valued at $1,476,000 after acquiring an additional 163 shares in the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 15,000 shares of the firm’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $401.44, for a total value of $6,021,600.00. Following the completion of the sale, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at $1,034,510.88. This trade represents a 85.34 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Judy D. Olian sold 1,750 shares of the business’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $412.48, for a total transaction of $721,840.00. Following the transaction, the director now directly owns 5,655 shares in the company, valued at approximately $2,332,574.40. The trade was a 23.63 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 117,496 shares of company stock worth $43,765,042. Insiders own 11.90% of the company’s stock.

Wall Street Analysts Forecast Growth

UTHR has been the topic of a number of research reports. Jefferies Financial Group raised their target price on shares of United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a research report on Monday, September 23rd. HC Wainwright lifted their price objective on shares of United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a report on Thursday, October 31st. LADENBURG THALM/SH SH upped their target price on United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. StockNews.com raised United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. Finally, Argus boosted their price target on United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. One analyst has rated the stock with a sell rating, two have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $370.86.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR opened at $372.89 on Friday. United Therapeutics Co. has a 1 year low of $208.62 and a 1 year high of $417.82. The firm has a market capitalization of $16.65 billion, a PE ratio of 16.38, a P/E/G ratio of 1.07 and a beta of 0.56. The business’s 50 day moving average price is $365.06 and its 200-day moving average price is $331.82.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.16 by $0.23. The business had revenue of $748.90 million during the quarter, compared to analyst estimates of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company’s revenue for the quarter was up 22.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $5.38 earnings per share. As a group, analysts expect that United Therapeutics Co. will post 25.22 earnings per share for the current year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.